Skip to main content
Category

News Archive

Medimmune logo

AstraZeneca plc: MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology

By News Archive

Medimmune logo

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses. This agreement will allow MedImmune to combine key agents from its investigational immunotherapy portfolio with Omnis’ lead investigational oncolytic virus programme, a genetically engineered strain of vesicular stomatitis virus (VSV). The programme is currently being studied in a Phase I clinical trial as a monotherapy for the treatment of hepatocellular carcinoma and other cancers that have metastasised to the liver.

Read More
greater-baltimore-committee-logo

Angel investor tax credit could make Maryland more appealing to investors, entrepreneurs – Baltimore Business Journal

By News Archive

greater-baltimore-committee-logo

Washington, D.C., Philadelphia, New York — Maryland has a lot of competition for entrepreneurs’ attention. Experts say a tax credit specifically for angel investors could sweeten the deal for entrepreneurs and investors who decide to do business in Maryland.

Establishing an angel investor tax credit will be a top priority for the Greater Baltimore Committee during the state’s upcoming legislative session. GBC sees the tax credit as a way to boost the state’s economy by supporting growing startups that will create jobs and bring new business to Maryland. Investors and adivsors of Baltimore-area startups say the tax credit would not only help startups grow in Maryland, but keep them — and their investors — from laying roots elsewhere.

Read More
Qiagen

Qiagen (QGEN) Launches Next-Gen TB Infection Test – Zacks.com

By News Archive

Qiagen

Sample and assay technologies provider Qiagen NV recently announced the launch of its latest diagnostic TB test– QuantiFERON-TB Gold-Plus (QFT-Plus), subsequent to the product’s receipt of CE Mark in Europe.

QFT-Plus is the fourth generation of the most accurate test used in the diagnosis of tuberculosis (TB) infection. It involves Qiagen’s proprietary QuantiFERON technology which can uniquely identify presymptomatic infections that standard diagnostic technologies fail to detect.

Read More
alexandria-real-estate-logo

Alexandria Real Estate seeking to raise $20 million to back digital health in S.F. – The Technology Chronicles

By News Archive

alexandria-real-estate-logo

Alexandria Real Estate Equities, the real estate firm that helped transform Mission Bay into a thriving life-science hub, now wants to raise up to $20 million to build digital-health companies from scratch in San Francisco.

Alexandria, the nation’s largest owner and developer of real estate for the life-science industry, said in August that it would start three new accelerators nationwide to support startups in biotech, agriculture and digital health. The biotech space is up and running in New York City with $51 million in financing, and the agriculture space is expected to open within the next six months in North Carolina.

Read More
Novartis-logo

Qualcomm and Novartis Part 2: Let’s start an investment company

By News Archive

novartis-logo

The Beyond the Pill movement took an interesting turn this week when Qualcomm announced plans to open an investment business with Novartis, according to a company statement. Qualcomm will launch the investment company through its Qualcomm Ventures business. The news splash at the start of the JP Morgan Healthcare conference came about a week after the two companies said at the International CES in Las Vegas that they would collaborate on digital health as part of Novartis’ Trials of the Future program.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.